Evidence map›Paper›PMID 24707440›Full record

ArticleISRN inflammation2014

Scientific Validation of Gentiana kurroo Royle for Anti-Inflammatory and Immunomodulatory Potential.

Khan Mubashir, Khalid Ghazanfar, Bashir A Ganai, Seema Akbar, Akhtar H Malik, Akbar Masood

Abstract read
In one paragraph

Article in ISRN inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Comparative analysis ofPharmaceutical biology · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Scientific Study of Gentiana kurroo Royle.Medicines (Basel, Switzerland) · 2017
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Khan MubashirDepartment of Biochemistry, University of Kashmir, Srinagar 190 006, India.
Khalid GhazanfarRegional Research Institute of Unani Medicine, Kashmir University Campus, Srinagar 190 006, India.ORCID 0000-0001-5323-6269
Bashir A GanaiDepartment of Biochemistry, University of Kashmir, Srinagar 190 006, India.
Seema AkbarRegional Research Institute of Unani Medicine, Kashmir University Campus, Srinagar 190 006, India.
Akhtar H MalikCentre for Biodiversity and Taxonomy (CBT), Department of Botany, University of Kashmir, Srinagar 190 006, India.
Akbar MasoodDepartment of Biochemistry, University of Kashmir, Srinagar 190 006, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gentiana kurroo Royle is a critically endangered medicinal plant species endemic to the northwestern Himalayas. This plant was studied for the immunomodulatory and anti-inflammatory potential. Carrageenan paw edema model was used to study the potential of the drug in inflammation in Wistar rats. SRBC specific haemagglutination titre and DTH assays were carried out in Balb/C mice for observing the effect of test drugs on immune system. The plant extracts were found to be active against inflammation. The methanolic fraction was observed to be the most effective in inhibition of paw edema with the inhibitory potential of 47.62%. In immunomodulation studies the plant extracts showed the immunosuppressant activity. Methanolic fraction was observed to have maximum potential for the suppression of both humoral (57.57% and 54.05%) and cell mediated immunity (65.27% and 75%). From these studies, it can be concluded that the extracts of plant are having anti-inflammatory and immunosuppressant activity. Since in chronic inflammation like arthritis there is the involvement of immune system, this plant may serve as an alternative for the treatment of autoimmune diseases like arthritis.

Identifiers

PMID24707440
PMCPMC3953469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.